Autologous non-bulbar dermal sheath derived fibroblast (Tendon injuries, RepliCel Life Sciences) 

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAutologous non-bulbar dermal sheath derived fibroblast (Tendon injuries, RepliCel Life Sciences) 
Drug Alias NameAutologous-cultured-fibroblasts-RepliCelRCT-A-01RCT-P-01Autologous non-bulbar dermal sheath fibroblast therapy (RepliCel Life Sciences)NBDS fibroblast therapy - RepliCel +[8] 
ClassificationCell and gene therapy > Cell therapy > Source of cells > Hair follicle-derivedCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Somatic cell > Dermal sheath cell therapy
Mechanisms of ActionTissue replacements
TargetsNot applicable
Therapy Area/IndicationsSkin AgingTendinopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesReplicel Life Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesReplicel Life Sciences Inc
Active IndicationsN/A
Inactive IndicationsSkin AgingTendinopathy

Other Information

ATC CodeN/A
Related LinksN/A